BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 30971472)

  • 1. Mechanisms of B-Cell Oncogenesis Induced by Epstein-Barr Virus.
    Saha A; Robertson ES
    J Virol; 2019 Jul; 93(13):. PubMed ID: 30971472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus (EBV) and lymphomagenesis.
    Cesarman E
    Front Biosci; 2002 Feb; 7():e58-65. PubMed ID: 11815280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA Sequencing Analyses of Gene Expression during Epstein-Barr Virus Infection of Primary B Lymphocytes.
    Wang C; Li D; Zhang L; Jiang S; Liang J; Narita Y; Hou I; Zhong Q; Zheng Z; Xiao H; Gewurz BE; Teng M; Zhao B
    J Virol; 2019 Jul; 93(13):. PubMed ID: 31019051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr Virus Facilitates Expression of KLF14 by Regulating the Cooperative Binding of the E2F-Rb-HDAC Complex in Latent Infection.
    Pei Y; Wong JH; Jha HC; Tian T; Wei Z; Robertson ES
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32847849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An EBNA3A-Mutated Epstein-Barr Virus Retains the Capacity for Lymphomagenesis in a Cord Blood-Humanized Mouse Model.
    Romero-Masters JC; Ohashi M; Djavadian R; Eichelberg MR; Hayes M; Zumwalde NA; Bristol JA; Nelson SE; Ma S; Ranheim EA; Gumperz JE; Johannsen EC; Kenney SC
    J Virol; 2020 May; 94(10):. PubMed ID: 32132242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BHLF1 Locus of Epstein-Barr Virus Contributes to Viral Latency and B-Cell Immortalization.
    Yetming KD; Lupey-Green LN; Biryukov S; Hughes DJ; Marendy EM; Miranda JL; Sample JT
    J Virol; 2020 Aug; 94(17):. PubMed ID: 32581094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
    Kalla M; Hammerschmidt W
    Eur J Cell Biol; 2012 Jan; 91(1):65-9. PubMed ID: 21450364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-9 Facilitates Epstein-Barr Virus Latent Infection and Lymphomagenesis in Human B Cells.
    Xu JX; Zhang R; Huang DJ; Tang Y; Ping LQ; Huang BJ; Huang HQ; Busson P; Li J
    Microbiol Spectr; 2023 Feb; 11(1):e0493222. PubMed ID: 36622166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors.
    White RE; Rämer PC; Naresh KN; Meixlsperger S; Pinaud L; Rooney C; Savoldo B; Coutinho R; Bödör C; Gribben J; Ibrahim HA; Bower M; Nourse JP; Gandhi MK; Middeldorp J; Cader FZ; Murray P; Münz C; Allday MJ
    J Clin Invest; 2012 Apr; 122(4):1487-502. PubMed ID: 22406538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
    Leong IT; Fernandes BJ; Mock D
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Epstein-barr virus gene expression in latent infection and B-lymphocyte growth transformation].
    Harada S
    Uirusu; 2002 Jun; 52(1):129-34. PubMed ID: 12227161
    [No Abstract]   [Full Text] [Related]  

  • 13. An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model.
    Romero-Masters JC; Ohashi M; Djavadian R; Eichelberg MR; Hayes M; Bristol JA; Ma S; Ranheim EA; Gumperz J; Johannsen EC; Kenney SC
    PLoS Pathog; 2018 Aug; 14(8):e1007221. PubMed ID: 30125329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice.
    Coleman CB; Lang J; Sweet LA; Smith NA; Freed BM; Pan Z; Haverkos B; Pelanda R; Rochford R
    J Virol; 2018 Nov; 92(21):. PubMed ID: 30089703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Host Biomarkers of Epstein-Barr Virus Latency IIb and Latency III.
    Messinger JE; Dai J; Stanland LJ; Price AM; Luftig MA
    mBio; 2019 Jul; 10(4):. PubMed ID: 31266868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.
    Price AM; Messinger JE; Luftig MA
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29118124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomics and Transcriptomics of BJAB Cells Expressing the Epstein-Barr Virus Noncoding RNAs EBER1 and EBER2.
    Pimienta G; Fok V; Haslip M; Nagy M; Takyar S; Steitz JA
    PLoS One; 2015; 10(6):e0124638. PubMed ID: 26121143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear receptors and their role in Epstein -- Barr virus induced B cell transformation.
    Yenamandra SP; Klein G; Kashuba E
    Exp Oncol; 2009 Jun; 31(2):67-73. PubMed ID: 19550394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
    Longnecker R
    Adv Cancer Res; 2000; 79():175-200. PubMed ID: 10818681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency.
    Dheekollu J; Malecka K; Wiedmer A; Delecluse HJ; Chiang AK; Altieri DC; Messick TE; Lieberman PM
    Oncotarget; 2017 Jan; 8(5):7248-7264. PubMed ID: 28077791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.